Usage Examples
- The implant is Class III, so there is no predicate argument to make and we are on the PMA path.
- That design change affects safety, so it needs an approved PMA supplement before we ship a single unit.
- If the reclassification petition succeeds and it drops to Class II, the whole clinical programme changes shape.
What is Class III Medical Device?
Class III medical devices are the FDA's highest-risk device class, covering devices that are life-supporting, life-sustaining, or present a potential unreasonable risk of illness or injury, and require premarket approval rather than 510(k) clearance.
Class III medical devices exist as a separate class because two lighter tiers of regulation run out of road. General controls handle registration, labelling, and adulteration. Special controls add performance standards and postmarket surveillance. When a device sustains a life or can cause unreasonable harm, neither tier produces the evidence a reviewer needs, so Class III attaches the obligation the other classes avoid: proof before market.
Class III covers devices where general and special controls cannot provide reasonable assurance of safety and effectiveness and the device is life-supporting, life-sustaining, of substantial importance in preventing impairment of human health, or presents a potential unreasonable risk of illness or injury. Class III does not automatically mean a PMA today: preamendments devices on the market before May 28, 1976, and devices substantially equivalent to them, remain on 510(k) until FDA calls for PMAs (21 CFR 814.1).
Class III sponsors build the programme backwards from the application. Clinical evidence normally comes from an IDE study, and the PMA must carry the full clinical investigation results plus a summary of them. Class III evidence is judged as valid scientific evidence, which 21 CFR 860.7 extends beyond well-controlled investigations to partially controlled studies, documented case histories by qualified experts, and significant human experience with a marketed device.
Not to be confused with
- Class II Device
- Class II devices reach market on special controls plus a 510(k); Class III is the class where those controls cannot supply the assurance, so an original evidence package is required instead of a comparison.
- 510(k) / Substantial Equivalence
- a 510(k) argues the device is substantially equivalent to a legally marketed predicate. A Class III PMA proves safety and effectiveness on the device's own evidence; the equivalence argument is not available.
- PMA
- PMA is the application; Class III is the classification that triggers it. A device is classified first, and the class determines whether a PMA is the required route.
- IDE
- an IDE authorises the clinical investigation that generates the evidence. An IDE never permits commercial distribution of a Class III device; only an approved PMA does.
Class III obligations run from classification through the life of the approved product.
What you must do
- 1Establish that the device meets the Class III criteria: general and special controls cannot provide reasonable assurance of safety and effectiveness, and the device is life-supporting, life-sustaining, of substantial importance in preventing impairment of human health, or presents a potential unreasonable risk of illness or injury21 CFR 860.3
- 2Submit the results of the clinical investigations involving human subjects, including protocols, number of investigators and subjects per investigator, subject selection and exclusion criteria, study population, study period, safety and effectiveness data, and adverse reactions and complications, together with a summary of those investigations21 CFR 814.20(b)
- 3Manage amendments during review so a major amendment is not triggered; FDA reviews an accepted PMA within 180 days where the applicant submits no major amendment21 CFR 814.44
- 4Submit a PMA supplement and obtain FDA approval before making any change affecting the safety or effectiveness of the approved device21 CFR 814.39(a)
- 5Satisfy the postapproval conditions FDA imposes, including continuing evaluation and periodic reporting on the safety, effectiveness, and reliability of the device for its intended use21 CFR 814.82
Common mistakes
Assuming a predicate exists before confirming the class
teams scope a 510(k), build a comparison table, and discover late that the device meets the Class III criteria in 21 CFR 860.3. The cost is not a resubmission, it is the missing clinical programme: a PMA needs its own evidence, and that evidence starts with an IDE study nobody budgeted.
Treating post-approval design changes as internal engineering
21 CFR 814.39(a) requires an approved PMA supplement before making a change affecting the safety or effectiveness of the device. Implementing first and filing after converts an engineering decision into a device distributed outside the terms of its approval.
Planning the launch against the 180-day clock
21 CFR 814.44 gives FDA 180 days on an accepted application only where no major amendment is submitted. The 180 days measure FDA's time, not the sponsor's; a deficiency response that qualifies as a major amendment extends the review, and advisory committee scheduling sits outside the number entirely.
When This Matters
- The implant is Class III, so there is no predicate argument to make and we are on the PMA path.
- That design change affects safety, so it needs an approved PMA supplement before we ship a single unit.
- If the reclassification petition succeeds and it drops to Class II, the whole clinical programme changes shape.
Frequently Asked Questions
Rarely. Class III is defined as the class of devices for which premarket approval is or will be required (21 CFR 860.3). The narrow exception in 21 CFR 814.1 covers preamendments Class III devices on the market before May 28, 1976 and devices substantially equivalent to them, which stay on 510(k) until FDA calls for PMAs.
Related Use Cases
- Medical Devices Use Cases
Prepare 510(k), PMA, and De Novo submissions with AI-guided pathway selection
- Consulting Use Cases
Manage 15+ client programs from one dashboard with per-client workspaces and tracking
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- Quality/QA Workflows
Track GxP regulation changes and enforcement trends
